Article
Clinical Neurology
Thien Phu Do, Christina Deligianni, Sarkhan Amirguliyev, Josefin Snellman, Cristina Lopez Lopez, Mohammad Al-Mahdi Al-Karagholi, Song Guo, Messoud Ashina
Summary: This study found that migraine attacks can be triggered by cAMP-mediated mechanisms without the activation of CGRP receptors. This opens up new possibilities for the development of mechanism-based drugs for the treatment of migraines.
Article
Pharmacology & Pharmacy
Michael L. Garelja, Tyla I. Alexander, Amy Bennie, Mhairi Nimick, Jakeb Petersen, Christopher S. Walker, Debbie L. Hay
Summary: This study demonstrates that erenumab can antagonize both CGRP and AMY(1) receptors, providing insights into the clinical profile of erenumab.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ahasanul Hasan, Raquibul Hasan
Summary: Empagliflozin induces vasodilation in rat mesenteric arteries by stimulating smooth muscle cell K-V channels, specifically K(V)1.5 and K(V)7. Inhibition of vasodilatory signaling axes and prostacyclin does not affect empagliflozin-induced vasodilation, indicating a novel mechanism for arterial relaxation. These findings suggest that empagliflozin may have potential as a complementary treatment for hypertension due to its effects on arterial contractility.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biology
Busecan Aksoydan, Serdar Durdagi
Summary: In this study, the structural and dynamical effects of RAMP1 on CGRPR inhibitors binding were investigated using molecular modeling and simulations. Results showed that the inhibitors can bind to both extracellular and transmembrane binding sites, with interactions at the transmembrane site being weak. In silico experiments confirmed the putative binding pocket for gepants at CGRPRs.
COMPUTERS IN BIOLOGY AND MEDICINE
(2022)
Review
Clinical Neurology
Michael L. Garelja, Debbie L. Hay
Summary: A comprehensive understanding of the pharmacology and relationship to migraine of the calcitonin peptide family of receptors is important in the development of new anti-migraine drugs and the interpretation of the mechanism of action of current drugs.
Article
Clinical Neurology
Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Feng Zhang, Gregory A. Rippon, Sunfa Cheng, Daniel D. Mikol
Summary: During long-term erenumab treatment, over half of patients with chronic migraine reverted to episodic migraine, with most of them experiencing persistent reversion. Some patients may achieve delayed reversion to episodic migraine.
Article
Clinical Neurology
David Kudrow, Rima Dafer, David W. Dodick, Amaal Starling, Jessica Ailani, Carrie Dougherty, Kavita Kalidas, Feng Zhang, Rohini Jeswani, Nishil Patel, Ani C. Khodavirdi
Summary: This study aimed to evaluate the cardiovascular safety of erenumab in migraine patients with pre-existing cardiovascular risk factors. The analysis showed no significant worsening of blood pressure in erenumab-treated patients regardless of baseline blood pressure category. The incidence rates of ischemic cardiovascular and cerebrovascular adverse events were low and similar across different cardiovascular risk categories.
Article
Clinical Neurology
David W. Dodick, Andrew M. Blumenfeld, Rashmi B. Halker Singh, Rachel Williams, Feng Zhang, Po-Wei Chen, Cheng-Pang Hsu, Cheng Peng, Josefin Snellman, Mahan Chehrenama, Jessica Ailani
Summary: This study found no evidence of systematic wearing-off with erenumab treatment. Further research is needed to determine if the reported wearing-off in some patients reflects a true treatment response pattern or normal fluctuations in migraine frequency.
Review
Pharmacology & Pharmacy
Ilana B. Kotliar, Emily Lorenzen, Jochen M. Schwenk, Debbie L. Hay, Thomas P. Sakmar
Summary: G protein-coupled receptors (GPCRs) interact with a variety of membrane proteins, but the extent and mechanisms of these interactions are not well understood. RAMPs, a class of GPCR-interacting proteins, have been extensively studied. Recent research suggests that GPCR-RAMP interactions may be more widespread than previously thought. This review summarizes the latest techniques for discovering GPCR-RAMP interactions and their functional consequences, and discusses future research prospects.
PHARMACOLOGICAL REVIEWS
(2023)
Editorial Material
Clinical Neurology
Enrico Bentivegna, Dilara Onan, Paolo Martelletti
Summary: Migraine is the main cause of work disability in young women and the second in the general population. Preventive treatment can improve the quality of life by reducing the frequency and intensity of attacks. However, there are significant gaps in the global health systems in terms of optimal management of preventive therapy. Traditional medications with known adverse effects are still considered the standard of care for migraine prevention in many cases, while the use of calcitonin gene-related peptide (CGRP) receptor antagonists is limited due to their high cost. There are also shortcomings in migraine management by general practitioners and a lack of patient education, resulting in delays in referring patients to specialized headache centers. We expect the headache medicine community to address these gaps in preventive treatment of migraine in the coming years.
NEUROLOGY AND THERAPY
(2023)
Article
Anesthesiology
David A. C. Messerer, Thomas Datzmann, Anke Baranowsky, Leandra Peschel, Andrea Hoffmann, Michael Groeger, Michael Amling, Martin Wepler, Benedikt L. Nussbaum, Shan Jiang, Paul Knapstein, Antonia Donat, Enrico Calzia, Peter Radermacher, Johannes Keller
Summary: The study found that CGRP receptor antagonism with olcegepant was not beneficial in a porcine model of polymicrobial sepsis, which closely mimics human sepsis.
BRITISH JOURNAL OF ANAESTHESIA
(2022)
Review
Medicine, General & Internal
Zizhen Zhang, Yunfeng Shu, Yun Diao, Yang Du, Lizhi Chen, Ying Liu, Biao Du
Summary: This study systematically evaluated the efficacy and safety of ubrogepant for acute migraine treatment, finding that ubrogepant group had significantly higher percentages of pain relief and symptom absence at 2 hours postdose compared to the placebo group, with similar incidence rates of common adverse events between the two groups.
Review
Clinical Neurology
Ahmed Taher Masoud, Mohammed Tarek Hasan, Ahmed Sayed, Harvey Nabil Edward, Ahmed Mohamed Amer, Abdelrahman Elshahat Naga, Mohamed Elfil, Badrah S. Alghamdi, Asma Perveen, Ghulam Md Ashraf, Eshak Bahbah
Summary: The study evaluated the efficacy of different CGRP receptor blockers for migraine treatment through systematic review and network meta-analysis. Results showed that Fremanezumab was the most effective drug for reducing monthly headache days in both chronic and episodic patients after six weeks, while Erenumab showed superior efficacy in the longer term. In chronic migraine patients, Fremanezumab, Erenumab, and Erenumab were associated with the highest efficacy after 6, 8, and 12 weeks, respectively.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Neurosciences
Lu Liu, Xiao-Bai Xu, Zheng-Yang Qu, Luo-Peng Zhao, Claire-Shuiqing Zhang, Zhi-Juan Li, Tian-Li Lyu, Xue-Fei Wang, Xiang-Hong Jing, Bin Li
Summary: The study shows that 5-HT7R plays a role in the antihyperalgesic effects of electroacupuncture by regulating PKA and ERK1/2 signaling pathways, reducing neurogenic inflammatory pain caused by migraines. Electroacupuncture increases pain thresholds and alleviates neuronal hyperexcitability in the trigeminal nucleus caudalis.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Neurosciences
Yanbo Yang, Mingjia Chen, Da Wu, Yue Sun, Fan Jiang, Zhouqing Chen, Zhong Wang
Summary: This study evaluated the safety and efficacy of erenumab in patients with episodic migraine and prior migraine treatment failures. The results showed that erenumab significantly reduced monthly migraine days and increased response rate. Higher dosage of erenumab was associated with better efficacy outcomes, without increased risk of adverse events. There was no significant difference in safety outcomes between different dosage groups.
CURRENT NEUROPHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Pabitra Hriday Patra, Eleni Serafeimidou-Pouliou, Michael Bazelot, Benjamin Jason Whalley, Claire Michelle Williams, Alister James McNeish
BRITISH JOURNAL OF PHARMACOLOGY
(2020)
Article
Clinical Neurology
Katie M. Linstra, Khatera Ibrahimi, Daphne S. van Casteren, Marieke J. H. Wermer, Gisela M. Terwindt, Antoinette MaassenVandenBrink
Summary: This study investigated pain perception in women with menstrually-related migraine throughout different phases of the menstrual cycle. Results showed that women with migraine had lower levels of trigeminal pain compared to healthy controls throughout the cycle, indicating that pain perception varies during the menstrual cycle.
Review
Pharmacology & Pharmacy
Cristiana-Ioana Bercea, Graeme S. Cottrell, Francesco Tamagnini, Alister J. McNeish
Summary: Hypertension is characterised by impaired vasodilation, which can be improved by omega-3 polyunsaturated fatty acids such as DHA and EPA. These fatty acids also have vasodilatory effects on vascular smooth muscle cells (VSMCs) by opening potassium channels and possibly voltage-activated potassium channels, leading to hyperpolarisation and relaxation. Structural manipulation of omega-3 PUFAs may lead to novel therapeutic strategies.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Clinical Neurology
Daphne S. van Casteren, Iris E. Verhagen, Gerrit L. J. Onderwater, Antoinette MaassenVanDenBrink, Gisela M. Terwindt
Summary: The study showed that females report migraine trigger factors more frequently than males, with menstruation, stress, and bright light being the top triggers for women. Women tend to report more triggers and have a lower migraine threshold compared to men, potentially due to hormonal changes.
Review
Clinical Neurology
Daphne S. van Casteren, Tobias Kurth, A. H. Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink
Summary: Our study found that men had a lower risk for headache recurrence and adverse events in response to triptans, as well as lower drug exposure compared to women. Despite higher drug exposure, women had higher headache recurrence rates possibly due to sex hormonal changes in longer attack duration.
Article
Pharmacology & Pharmacy
Tessa de Vries, Linda Al-Hassany, Antoinette MaassenVanDenBrink
Summary: Rimegepant, a small-molecule CGRP receptor antagonist, is well tolerated and effective for acute migraine treatment. However, its therapeutic gain is modest, and the long-term consequences of CGRP blockade require further research.
EXPERT OPINION ON PHARMACOTHERAPY
(2021)
Review
Geriatrics & Gerontology
Simone de Vries Lentsch, Eloisa Rubio-Beltran, Antoinette MaassenVanDenBrink
Summary: Migraine is a neurovascular disorder more prevalent in women, driving the urgent need for new preventive medications. Current research targeting CGRP has shown significant effects in clinical trials for prevention and acute treatment of migraine. Further exploration is needed to understand the potential gender-specific differences in CGRP response and potential cardiovascular risks associated with targeting the CGRP pathway in female migraine patients.
Article
Clinical Neurology
Daphne S. van Casteren, Iris E. Verhagen, Irene de Boer, Simone de Vries Lentsch, Rolf Fronczek, Erik W. van Zwet, Antoinette MaassenVanDenBrink, Gisela M. Terwindt
Summary: The study showed that the E-diary is useful in diagnosing migraine and can help patients accurately record the number of headache and migraine days, providing reliable information for healthcare providers.
Review
Clinical Neurology
Linda Al-Hassany, Antoinette MaassenVanDenBrink
Summary: There have been no reported pharmacokinetic interactions between triptans, ditans, and mAbs targeting CGRP or its receptor. However, there are potential risks, particularly in migraine patients with comorbid cardiovascular disease or with an increased cardiovascular risk profile. More research is needed to better understand the risks and interactions associated with the concurrent use of these drugs.
CURRENT OPINION IN NEUROLOGY
(2021)
Review
Clinical Neurology
Tatiane Teru Takahashi, Raffaele Ornello, Giuseppe Quatrosi, Angelo Torrente, Maria Albanese, Simone Vigneri, Martina Guglielmetti, Cristiano Maria De Marco, Camille Dutordoir, Enrico Colangeli, Matteo Fuccaro, Davide Di Lenola, Valerio Spuntarelli, Laura Pilati, Salvatore Di Marco, Annelies Van Dycke, Ramla Abuukar Abdullahi, Antoinette Maassen van den Brink, Paolo Martelletti
Summary: Chronic headaches are common in migraineurs and can progress to medication overuse headache (MOH). MOH is caused by overuse of painkillers or other medications. While head pain symptoms associated with medication overuse generally improve after stopping regular medication use, behavioral issues such as drug dependence may still persist.
JOURNAL OF HEADACHE AND PAIN
(2021)
Editorial Material
Pharmacology & Pharmacy
Alister J. McNeish
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Clinical Neurology
Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Karppa
Summary: The efficacy of fremanezumab in reducing migraine and headache days, acute medication use, and disability was demonstrated in patients with difficult-to-treat migraine, regardless of age or sex, according to the FOCUS study.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Cardiac & Cardiovascular Systems
Deborah N. Kalkman, Emile G. M. Couturier, Abdelhak El Bouziani, Jorge Dahdal, Jolien Neefs, Janneke Woudstra, Birgit Vogel, Daniela Trabattoni, Antoinette MaassenVanDenBrink, Roxana Mehran, Robbert J. de Winter, Yolande Appelman
Summary: Migraine is a chronic neurovascular disease with complex pathophysiology and multiple causes. Women are more likely to suffer from migraine, and it is the most disabling disease in women under 50 years old. Migraine with aura is associated with increased risk of cardiovascular diseases, such as stroke, atrial fibrillation, myocardial infarction, and cardiovascular death. Medications for migraine treatment may have potential risks for patients with cardiovascular disease. Further research is needed to understand the contraindications for newer treatments. This review discusses the pathophysiology, associations with cardiovascular diseases, current therapies, and future research directions.
EUROPEAN HEART JOURNAL
(2023)
Review
Clinical Neurology
Dimos D. Mitsikostas, Christian Waeber, Margarita Sanchez-del-Rio, Bianca Raffaelli, Hakan Ashina, Antoinette Maassen van den Brink, Anna Andreou, Patricia Pozo-Rosich, Alan Rapoport, Messoud Ashina, Michael A. Moskowitz
Summary: Migraine, a leading cause of disability in over one billion people globally, is underestimated even by those who suffer from it. Current treatments have limited efficacy and potential side effects, resulting in low treatment adherence. Recently, a new class of drugs called ditans, selective serotonin 5-HT1F receptor agonists, has been introduced to the international market. This article reviews preclinical studies from the late 1990s and recent clinical research that led to the development and approval of ditans for acute migraine treatment by the US FDA and the European Medicines Agency.
NATURE REVIEWS NEUROLOGY
(2023)
Article
Physiology
Dominique M. Bovee, Estrellita Uijl, David Severs, Eloisa Rubio-Beltran, Richard van Veghel, Antoinette Maassen van den Brink, Jaap A. Joles, Robert Zietse, Catherina A. Cuevas, A. H. Jan Danser, Ewout J. Hoorn
Summary: The study using the 5/6 nephrectomy rat model found that spironolactone was effective in reducing hypertension in the high-salt diet group, while targeting aldosterone, the mineralocorticoid receptor, and especially angiotensin II in the normal-salt diet group could lower blood pressure.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2021)